Get the Stockscreener App
129.18
2.32%
2.93
Illumina Inc stock is traded at $129.18, with a volume of 1.16M.
It is up +2.32% in the last 24 hours and up +7.90% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$126.25
Open:
$126.31
24h Volume:
1.16M
Relative Volume:
0.53
Market Cap:
$20.58B
Revenue:
$4.43B
Net Income/Loss:
$-3.04B
P/E Ratio:
-4.8546
EPS:
-26.61
Net Cash Flow:
$357.00M
1W Performance:
+3.85%
1M Performance:
+7.90%
6M Performance:
-2.71%
1Y Performance:
-14.32%
1-Day Range:
$126.31
$129.71
1-Week Range:
$120.51
$129.71
52-Week Range:
$89.00
$152.87
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Wilkins Investment Counsel Inc. Boosts Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Position Lifted by Federated Hermes Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Goldman Thinks Illumina, Inc. (ILMN) Is A Long-Term AI Stock Set To Rally Eventually - Yahoo Finance
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal - Benzinga
Wedbush Securities Inc. Sells 916 Shares of Illumina, Inc. (NASDAQ:ILMN) - Defense World
Los Angeles Capital Management LLC Has $843,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - Defense World
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights - GlobeNewswire Inc.
Argus Research Upgrades Illumina (ILMN) - MSN
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
North America Protein Chip Market Latest Growth and Insights - openPR
Headlands Technologies LLC Purchases 4,224 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
TD Asset Management Inc Sells 29,166 Shares of Illumina, Inc. (NASDAQ:ILMN) - Defense World
Illumina Inc. stock rises Wednesday, still underperforms market - MarketWatch
Daiwa Securities Group Inc. Grows Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
In Edinburgh, taking comprehensive genomic profiling to the next level - Illumina
EU Merger Control Concerns Remain After ECJ Illumina Ruling - Law360
Bull of the Day: Illumina (ILMN) - MSN
Microfluidic Market Growth and Future Outlook Industry - openPR
Commission withdraws several decisions in the Illumina/GRAIL case - EU Reporter
Vision Capital Management Inc. Sells 14,921 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Congress zeroes in on biotechs with connections to China. Here's one company's story - The Business Journals
Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Bull Of The Day: Illumina (ILMN) - Barchart
Bull of the Day: Illumina (ILMN) - Yahoo Finance
Bull of the Day: Illumina (ILMN) - Zacks Investment Research
DNA Sequencing Market Future Business Opportunities 2024-2031 | Thermo Fisher Scientific, Inc., Illumina, Inc - openPR
For the first time ever, gene expression can be mapped from space - Illumina
Illumina Strategically Manages Debt and Issues New Notes - TipRanks
Rocket Stock Down More Than 30% in Past Six Months: Here's Why - Benzinga
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - Benzinga
Illumina court ruling limits EU regulators’ merger review power - MedTech Dive
A step toward better health outcomes in India - Illumina
FDA Approves Illumina's TruSight Oncology Comprehensive Assay, Now Offered by PreCheck Health Services as "SolidTumorCheck+" -- A Breakthrough in Precision Oncology - Longview News-Journal
Certuity LLC Makes New $881,000 Investment in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
FDA Approves Illumina Cancer Biomarker Test - San Diego Business Journal
Allspring Global Investments Holdings LLC Has $88,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN) - Defense World
Unparalleled Research on Next-Generation Sequencing Analysis - openPR
Epigenetics Market Projections: Industry Growth and Size - openPR
New Mexico Educational Retirement Board Acquires 24,350 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Candriam S.C.A. Boosts Stock Position in Illumina, Inc. (NASDAQ:ILMN) - Defense World
Weil Company Inc. Sells 5,266 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
EU Antitrust Chief Charts Path Forward After Illumina Setback - Law360
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Kornitzer Capital Management Inc. KS Sells 4,142 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Rhumbline Advisers Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN) - Defense World
Whole Genome Bisulfite Sequencing (WGBS) Market Key Dynamics - openPR
Illumina wins Grail battle in blow to EU merger power - Yahoo Finance UK
Illumina Wins Appeal in Europe Over Grail Acquisition, Avoids €432M Fine - Zenopa
Opinion | Illumina’s Antitrust Vindication - The Wall Street Journal
Illumina decision: ‘Blow to the Commission’s quick-fix merger rules’ - International Financial Law Review
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):